button bars forest bayes pooled summary circles
benefit
(statisticaly significant) 		benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population

versus gemcitabine plus platin
atezolizumab alone vs. gemcitabine plus platin 1 NS--
durvalumab alone vs. gemcitabine plus platin 1 NSNS-
durvalumab plus tremelimumab vs. gemcitabine plus platin 1 NSNS-
pembrolizumab plus SoC vs. gemcitabine plus platin 1 NS-22%-
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 -17%-18%-
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 NS+35%-

mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive

versus gemcitabine plus platin
durvalumab alone vs. gemcitabine plus platin 1 NSNS-
durvalumab plus tremelimumab vs. gemcitabine plus platin 1 -26%NS-

mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 1 -15%NS-
pembrolizumab alone vs. Standard of Care (SoC) 1 -27%NS-

mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 2 NSNS-
pembrolizumab alone vs. Standard of Care (SoC) 1 -43%NS-

mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population

versus BSC
avelumab alone vs. BSC 1 -31%-38%-

mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive

versus BSC
avelumab alone vs. BSC 1 -44%-44%-

MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population

versus no additional treatment
atezolizumab alone vs. no additional treatment 1 ---
versus placebo
nivolumab alone vs. placebo 1 ---28%

MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive

versus placebo
nivolumab alone vs. placebo 1 ---45%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons